We use cookies to help provide you with the best possible online experience. Please read our Privacy Policy for information about which cookies we use and what information we collect on our site. By continuing to use this site, you agree that we may store and access cookies on your device.
Daiichi Sankyo announced positive top-line results from REDUCER (an Asian, phase 3, multicenter, RandomizEd, Double-blind, placebo-controlled 14-week stUdy of mirogabalin in patients with diabetiC pEripheral neuRopathic pain, followed by a 52-week open-la